Last reviewed · How we verify
Benzoyl peroxide 3%
At a glance
| Generic name | Benzoyl peroxide 3% |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Positive Assurance and mTBI (NA)
- Functional Instability in Patients Suffering From Collagen Disease and Joint Hypermobility
- An Observational Clinical Study to Evaluate the Efficacy of the CeraVe Skin Care Line
- Benzydamine Hydrochloride and Post-operative Sore Throat (EARLY_PHASE1)
- The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment (PHASE2)
- An Investigation of a Multi-Function Skincare Product to Improve Aging, Eczema, and Acne Outcomes (NA)
- European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benzoyl peroxide 3% CI brief — competitive landscape report
- Benzoyl peroxide 3% updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI